<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="Albendazole" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">livertox</book-id>
    <book-title-group>
      <book-title>LiverTox</book-title>
      <subtitle>Clinical and Research Information on Drug-Induced Liver Injury</subtitle>
    </book-title-group>
    <pub-date date-type="pubr" publication-format="electronic">
      <year>2012</year>
    </pub-date>
    <publisher>
      <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
      <publisher-loc>Bethesda (MD)</publisher-loc>
    </publisher>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">Albendazole</book-part-id>
      <title-group>
        <title>Albendazole</title>
      </title-group>
      <pub-history>
        <date date-type="updated">
          <day>19</day>
          <month>2</month>
          <year>2016</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="livertox">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury</related-object>
      <related-object link-type="previous-part-link" source-id="livertox" document-id="Afatinib" document-type="chapter">Afatinib</related-object>
      <related-object link-type="next-part-link" source-id="livertox" document-id="Albiglutide" document-type="chapter">Albiglutide</related-object>
    </book-part-meta>
    <body>
      <sec id="Albendazole.OVERVIEW">
        <title>OVERVIEW</title>
        <sec id="Albendazole.Introduction" sec-type="pubmed-excerpt">
          <title>Introduction</title>
          <p>Albendazole is an anthelmintic agent used predominantly in treatment of echinococcosis, a parasitic worm that causes cysts in liver and lung. Albendazole therapy is commonly associated with mild and transient serum enzyme elevations and rarely can lead to clinically apparent acute liver injury.</p>
        </sec>
        <sec id="Albendazole.Background">
          <title>Background</title>
          <p>Albendazole (al ben' da zole) is a benzimidazole anthelmintic agent similar in structure and mechanism of action to thiabendazole and mebendazole and the veterinary agent fenbendazole. The benzimidazoles act by selective binding to beta-tubulin of parasitic worms, causing their immobilization and death. Albendazole has proven efficacy against several parasitic worms and was approved for use in the United States in 1996. Currently indications for albendazole include echnicoccosis, cysticercosis and strongyloidiasis against which it is more effective than mebendazole (largely because it is better absorbed). Albendazole is also used for hookworm, whipworm and pinworm infestations. Albendazole is available in tablets of 200 mg under the trade name of Albenza. The dose and duration of albendazole therapy varies by indication, being a single dose of 400 mg orally for minor infestations (which can be repeated a few weeks later), and 400 mg twice daily for 1 to 2 weeks or for up to 6 months for more serious systemic infections. Albendazole is generally well tolerated; side effects include gastrointestinal upset, headaches and hair loss.</p>
        </sec>
        <sec id="Albendazole.Hepatotoxicity">
          <title>Hepatotoxicity</title>
          <p>Albendazole therapy has been associated with transient and asymptomatic elevations in serum aminotransferase levels in up to 50% of patients treated for more than a few weeks. These abnormalities rapidly improve with stopping therapy which is rarely required (~4%). Albendazole has also been associated with rare instances of clinically apparent liver injury. The onset of injury has been within a few days to as long as 2 months of starting therapy or more rapidly with multiple courses of treatment. The injury can also arise 1 to 2 weeks after a short course of albendazole (1-3 days). The pattern of serum enzyme elevations is typically hepatocellular or mixed. Allergic features (rash, fever, eosinophilia) may be present but are not prominent. Most cases have been mild and recovery is distinctively rapid once the drug is stopped. Rapid recurrence with rechallenge has been reported but with similar severity.</p>
          <p>Likelihood score: B (highly likely cause of clinically apparent liver injury).</p>
        </sec>
        <sec id="Albendazole.Mechanism_of_Injury">
          <title>Mechanism of Injury</title>
          <p>Albendazole acts by binding tubulin in parasitic worms which it does with greater avidity than the tubulin in mammalian cells, but some of the toxicity of the benzimidazoles may be related to this tubulin-binding activity. In most instances of clinically apparent liver injury, hypersensitivity appears to be the cause. A similar cholestatic or mixed hepatitis has been described in dogs receiving fenbendazole.</p>
        </sec>
        <sec id="Albendazole.Outcome_and_Management">
          <title>Outcome and Management</title>
          <p>Albendazole is usually well tolerated and the liver injury reported with its use has been mild and self-limited in course. Nevertheless, routine monitoring of serum enzymes is recommending every 2 weeks when extended therapy is used. Patients with acute liver injury attributed to albendazole should avoid repeat exposure. Albendazole has not been associated with acute liver failure or chronic liver injury. It is unknown whether there is cross sensitivity with other benzimidazoles (such as mebendazole), but there probably is and switching to another class of anthelmintic agents is appropriate if therapy is still needed.</p>
          <p>Drug Class: <related-object link-type="booklink" source-id="livertox" document-id="AntihelminthicAgents" document-type="chapter">Anthelmintic Agents</related-object></p>
        </sec>
      </sec>
      <sec id="Albendazole.PRODUCT_INFORMATION">
        <title>PRODUCT INFORMATION</title>
        <p>
          <bold>REPRESENTATIVE TRADE NAMES</bold>
        </p>
        <p>Albendazole &#x02013; Albenza&#x000ae;</p>
        <p>
          <bold>DRUG CLASS</bold>
        </p>
        <p>Anthelmintic Agents</p>
        <p>
          <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=albendazole">COMPLETE LABELING</ext-link>
        </p>
        <p>Product labeling at DailyMed, National Library of Medicine, NIH</p>
      </sec>
      <sec id="Albendazole.CHEMICAL_FORMULA_AND_STRUCTU">
        <title>CHEMICAL FORMULA AND STRUCTURE</title>
        <table-wrap id="Albendazole.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_Albendazole.Tc_1_1_1_1" valign="top" align="left" scope="col" rowspan="1" colspan="1">DRUG</th>
                <th id="hd_h_Albendazole.Tc_1_1_1_2" valign="top" align="left" scope="col" rowspan="1" colspan="1">CAS REGISTRY NUMBER</th>
                <th id="hd_h_Albendazole.Tc_1_1_1_3" valign="top" align="left" scope="col" rowspan="1" colspan="1">MOLECULAR FORMULA</th>
                <th id="hd_h_Albendazole.Tc_1_1_1_4" valign="top" align="left" scope="col" rowspan="1" colspan="1">STRUCTURE</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_Albendazole.Tc_1_1_1_1" valign="top" align="left" scope="row" rowspan="1" colspan="1">Albendazole</td>
                <td headers="hd_h_Albendazole.Tc_1_1_1_2" valign="top" align="left" rowspan="1" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pubchem" xlink:href="sid://135003573">54965-21-8</ext-link>
                </td>
                <td headers="hd_h_Albendazole.Tc_1_1_1_3" valign="top" align="left" rowspan="1" colspan="1">C12-H15-N3-O2-S</td>
                <td headers="hd_h_Albendazole.Tc_1_1_1_4" valign="top" align="left" rowspan="1" colspan="1">
                  <related-object link-type="ext-image-back-link" source-id="pubchem" document-id="135003573" document-id-type="sid" document-type="summary" object-id="135003573" object-id-type="sid" object-type="image"/>
                </td>
              </tr>
            </tbody>
          </table>
        </table-wrap>
      </sec>
      <sec id="Albendazole.ANNOTATED_BIBLIOGRAPHY">
        <title>ANNOTATED BIBLIOGRAPHY</title>
        <p>References updated: 19 February 2016</p>
        <ref-list id="Albendazole.ANNOTATED_BIBLIOGRAPHY.reflist0">
          <ref id="Albendazole.REF.zimmerman.1999">
            <mixed-citation publication-type="book">Zimmerman HJ. Antihelminthics. Hepatic injury from antimicrobial agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 626-8.<annotation><p><italic toggle="yes">(Expert review of hepatotoxicity of anthelmintics written in 1999; albendazole is associated with serum aminotransferase elevations in 20% of patients and has been linked to rare instances of acute liver injury).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Albendazole.REF.mccarthy.2011">
            <mixed-citation publication-type="book">McCarthy J, Loukas A, Hotez PJ. Chemotherapy of helminth infections. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman&#x02019;s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1443-61.<annotation><p><italic toggle="yes">(Textbook of pharmacology and therapeutics).</italic></p></annotation></mixed-citation>
          </ref>
          <ref id="Albendazole.REF.morris.1987.343">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Morris</surname>
                  <given-names>DL</given-names>
                </name>
                <name name-style="western">
                  <surname>Smith</surname>
                  <given-names>PG</given-names>
                </name>
              </person-group>
              <article-title>Albendazole in hydatid disease&#x02014;hepatocellular toxicity.</article-title>
              <source>Trans R Soc Trop Med Hyg</source>
              <year>1987</year>
              <volume>81</volume>
              <fpage>343</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 40 patients treated with albendazole for echinococcosis, 6 had ALT elevations [62-970 U/L, Alk P ~360 U/L] and 1 jaundice [bilirubin 5.7 mg/dL], with rapid resolution on stopping; 2 had positive rechallenge).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3617201</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.choudhuri.1988.245">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Choudhuri</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Prasad</surname>
                  <given-names>RN</given-names>
                </name>
              </person-group>
              <article-title>Jaundice due to albendazole.</article-title>
              <source>Indian J Gastroenterol</source>
              <year>1988</year>
              <volume>7</volume>
              <fpage>245</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(30 year old man with echinococcal cyst developed jaundice 2.5 months after starting albendazole [bilirubin 5.6 mg/dL, ALT 320 U/L, Alk P 1.8 times ULN], resolving within 10 days of stopping; positive rechallenge with appearance of jaundice within two days).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">3182029</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.jagota.1989.58">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Jagota</surname>
                  <given-names>SC</given-names>
                </name>
              </person-group>
              <article-title>Jaundice due to albendazole.</article-title>
              <source>Indian J Gastroenterol</source>
              <year>1989</year>
              <volume>8</volume>
              <fpage>58</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Letter in response to Choudhuri and Prasad recommending limiting dose of albendazole to 400 mg twice daily in cycles of 28 days. Reply by authors stresses the elements of hypersensitivity in the case report).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">2914724</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.elmufti.1993.241">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>el-Mufti</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Kamag</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Ibrahim</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Taktuk</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Swaisi</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Zaidan</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Sameen</surname>
                  <given-names>A</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Albendazole therapy of hydatid disease: 2-year follow-up of 40 cases.</article-title>
              <source>Ann Trop Med Parasitol</source>
              <year>1993</year>
              <volume>87</volume>
              <fpage>241</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 40 Egyptian patients with echinococcal cysts treated with albendazole [usually in three 28 day cycles], hepatotoxicity arose in 2 patients [5%], both resolving on discontinuation; details not given, but Alk P said to be unreliable as a marker of liver injury because it is often raised before therapy).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8257234</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.gilgrande.1993.1269">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Gil-Grande</surname>
                  <given-names>LA</given-names>
                </name>
                <name name-style="western">
                  <surname>Rodriguez-Cabeiro</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>Prieto</surname>
                  <given-names>JG</given-names>
                </name>
                <name name-style="western">
                  <surname>Sanchez-Ruano</surname>
                  <given-names>JJ</given-names>
                </name>
                <name name-style="western">
                  <surname>Brasa</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Agular</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Garcia-Hoz</surname>
                  <given-names>F</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Randomised controlled trial of efficacy of albendazole in intra-abdominal hydatid disease.</article-title>
              <source>Lancet</source>
              <year>1993</year>
              <volume>342</volume>
              <fpage>1269</fpage>
              <lpage>72</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 43 patients treated with albendazole [10 mg/kg/day] for 10-111 days, 27 had ALT elevations during therapy, which were &#x0003e; twice ULN in 21 and &#x0003e;200 U/L in 4; liver biopsies showed &#x0201c;toxic hepatitis&#x0201d; and changes correlated with higher drug levels in liver; no jaundice or clinically apparent injury and all resolved).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">7901585</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.klion.1993.202">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Klion</surname>
                  <given-names>AD</given-names>
                </name>
                <name name-style="western">
                  <surname>Massougbodji</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Horton</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Ekou&#x000e9;</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Lanmasso</surname>
                  <given-names>T</given-names>
                </name>
                <name name-style="western">
                  <surname>Ahouissou</surname>
                  <given-names>NL</given-names>
                </name>
                <name name-style="western">
                  <surname>Nutman</surname>
                  <given-names>TB</given-names>
                </name>
              </person-group>
              <article-title>Albendazole in human loiasis: results of a double-blind, placebo-controlled trial.</article-title>
              <source>J Infect Dis</source>
              <year>1993</year>
              <volume>168</volume>
              <fpage>202</fpage>
              <lpage>6</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(23 patients with loiasis were treated with albendazole [n=11: 200 mg twice daily] or placebo [n=12] for 21 days; none developed ALT elevations or evidence of liver injury).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8515109</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.misra.1995.779">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Misra</surname>
                  <given-names>PK</given-names>
                </name>
                <name name-style="western">
                  <surname>Kumar</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Agarwal</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Jagota</surname>
                  <given-names>SC</given-names>
                </name>
              </person-group>
              <article-title>A comparative clinical trial of albendazole versus metronidazole in children with giardiasis.</article-title>
              <source>Indian Pediatr</source>
              <year>1995</year>
              <volume>32</volume>
              <fpage>779</fpage>
              <lpage>82</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Randomized trial of albendazole [400 mg/day for 5 days] vs metronidazole [7.5 mg/kg thrice daily for 5 days] in 64 children with giardiasis; all children were cured and side effects were similar, no differences in biochemical test results).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">8617554</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.horton.1997.79">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Horton</surname>
                  <given-names>RJ</given-names>
                </name>
              </person-group>
              <article-title>Albendazole in treatment of human cystic echinococcosis: 12 years of experience.</article-title>
              <source>Acta Trop</source>
              <year>1997</year>
              <volume>64</volume>
              <fpage>79</fpage>
              <lpage>93</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Current dose of albendazole for therapy of echinococcosis is 800 mg daily for ~3 months; serum enzyme elevations occurred in 10-20% of patients, requiring discontinuation in 4%, all cases were reversible, some possibly due to underlying liver cyst disease).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">9095290</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.molina.1998.1373">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Molina</surname>
                  <given-names>JM</given-names>
                </name>
                <name name-style="western">
                  <surname>Chastang</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Goguel</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Michiels</surname>
                  <given-names>JF</given-names>
                </name>
                <name name-style="western">
                  <surname>Sarfati</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Desportes-Livage</surname>
                  <given-names>I</given-names>
                </name>
                <name name-style="western">
                  <surname>Horton</surname>
                  <given-names>J</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Albendazole for treatment and prophylaxis of microsporidiosis due to Encephalitozoon intestinalis in patients with AIDS: a randomized double-blind controlled trial.</article-title>
              <source>J Infect Dis</source>
              <year>1998</year>
              <volume>177</volume>
              <fpage>1373</fpage>
              <lpage>7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Controlled trial of albendazole vs placebo in 8 patients with HIV and E. intestinalis infection; ALT elevations occurred in 1 patient in each group).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">9593027</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.inkatanuvat.1998.735">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Inkatanuvat</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Suntharasamai</surname>
                  <given-names>P</given-names>
                </name>
                <name name-style="western">
                  <surname>Vutikes</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Riganti</surname>
                  <given-names>M</given-names>
                </name>
              </person-group>
              <article-title>Changes of liver functions after albendazole treatment in human gnathostomiasis.</article-title>
              <source>J Med Assoc Thai</source>
              <year>1998</year>
              <volume>81</volume>
              <fpage>735</fpage>
              <lpage>40</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(98 patients with &#x0201c;gnathostomiasis&#x0201d; were given albendazole [800 mg daily] for 14 days; ALT elevations were present in 44% at day 14, 18% at day 28, peak values of 482 U/L, but all were asymptomatic and most returned to normal by 6 months).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">9803063</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.dunyo.2000.205">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Dunyo</surname>
                  <given-names>SK</given-names>
                </name>
                <name name-style="western">
                  <surname>Nkrumah</surname>
                  <given-names>FK</given-names>
                </name>
                <name name-style="western">
                  <surname>Simonsen</surname>
                  <given-names>PE</given-names>
                </name>
              </person-group>
              <article-title>A randomized double-blind placebo-controlled field trial of ivermectin and albendazole alone and in combination for the treatment of lymphatic filariasis in Ghana.</article-title>
              <source>Trans R Soc Trop Med Hyg</source>
              <year>2000</year>
              <volume>94</volume>
              <fpage>205</fpage>
              <lpage>11</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Placebo controlled trial of single dose of albendazole, ivermectin or the combination of both in 1425 persons from filariasis-endemic villages; albendazole therapy was associated with a modest but delayed reduction in microfilarial levels; side effects were mild and self-limited and not different from placebo; no mention of jaundice or hepatitis).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">10897370</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.shenoy.2002.603">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Shenoy</surname>
                  <given-names>RK</given-names>
                </name>
                <name name-style="western">
                  <surname>Suma</surname>
                  <given-names>TK</given-names>
                </name>
                <name name-style="western">
                  <surname>John</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Arun</surname>
                  <given-names>SR</given-names>
                </name>
                <name name-style="western">
                  <surname>Kumaraswami</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Fleckenstein</surname>
                  <given-names>LL</given-names>
                </name>
                <name name-style="western">
                  <surname>Na-Bangchang</surname>
                  <given-names>K</given-names>
                </name>
              </person-group>
              <article-title>The pharmacokinetics, safety and tolerability of the co-administration of diethylcarbamazine and albendazole.</article-title>
              <source>Ann Trop Med Parasitol</source>
              <year>2002</year>
              <volume>96</volume>
              <fpage>603</fpage>
              <lpage>14</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Pharmacokinetic studies of single oral doses of diethylcarbamazine and albendazole reported no drug-drug interactions and no adverse events).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">12396323</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.matthaiou.2008.e194">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Matthaiou</surname>
                  <given-names>DK</given-names>
                </name>
                <name name-style="western">
                  <surname>Panos</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Adamidi</surname>
                  <given-names>ES</given-names>
                </name>
                <name name-style="western">
                  <surname>Falagas</surname>
                  <given-names>ME</given-names>
                </name>
              </person-group>
              <article-title>Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.</article-title>
              <source>PLoS Negl Trop Dis</source>
              <year>2008</year>
              <volume>2</volume>
              <elocation-id>e194</elocation-id>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of efficacy of albendazole versus praziquantel; no differences in rates of adverse events, but no details given).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18335068</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.keiser.2008.1937">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Keiser</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Utzinger</surname>
                  <given-names>J</given-names>
                </name>
              </person-group>
              <article-title>Efficacy of current drugs against soil-transmitted helminth infections: systematic review and meta-analysis.</article-title>
              <source>JAMA</source>
              <year>2008</year>
              <volume>299</volume>
              <fpage>1937</fpage>
              <lpage>48</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of efficacy and safety of albendazole, mebendazole and pyrantel pamoate as therapy of A. Lumbricoides, hookworm and T. Tichiura; albendazole was well tolerated in most studies, no significant adverse events were reported).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18430913</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.choi.2008.903">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Choi</surname>
                  <given-names>GY</given-names>
                </name>
                <name name-style="western">
                  <surname>Yang</surname>
                  <given-names>HW</given-names>
                </name>
                <name name-style="western">
                  <surname>Cho</surname>
                  <given-names>SH</given-names>
                </name>
                <name name-style="western">
                  <surname>Kang</surname>
                  <given-names>DW</given-names>
                </name>
                <name name-style="western">
                  <surname>Go</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>WC</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>YJ</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Acute drug-induced hepatitis caused by albendazole.</article-title>
              <source>J Korean Med Sci</source>
              <year>2008</year>
              <volume>23</volume>
              <fpage>903</fpage>
              <lpage>5</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(47 year old man developed fever and rash 2 days after single dose of albendazole and 2 days later was jaundiced [bilirubin 2.8 mg/dL, ALT 4,622 U/L, Alk P 40 U/L, INR 1.44]; rapid recovery).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18955802</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.jevti_.2008.539">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Jevti&#x00107;</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Miki&#x00107;</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Arsi&#x00107;-Komljenovi&#x00107;</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Stankovi&#x00107;</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Ristanovi&#x00107;</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Sjenici&#x00107;</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Jani&#x00107;ijevi&#x00107;-Hudomal</surname>
                  <given-names>S.</given-names>
                </name>
              </person-group>
              <comment>[Adverse effects of longterm, continual administration of high doses of albendazole in the treatment of echinococcal disease]</comment>
              <source>Vojnosanit Pregl</source>
              <year>2008</year>
              <volume>65</volume>
              <fpage>539</fpage>
              <lpage>44</lpage>
              <comment>Serbian.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 42 patients with echinococcosis treated with albendazole for 4 to 6 months, ALT elevations occurred in 36% and led to discontinuation in 7%, subsequently resolving in all).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">18700464</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.miki_.2009.833">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Miki&#x00107;</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Jevti&#x00107;</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Arsi&#x00107;-Komljenovi&#x00107;</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Ristanovi&#x00107;</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Stankovi&#x00107;</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Sjenici&#x00107;</surname>
                  <given-names>G</given-names>
                </name>
                <name name-style="western">
                  <surname>Jani&#x00107;ijevi&#x00107;-Hudomal</surname>
                  <given-names>S.</given-names>
                </name>
              </person-group>
              <comment>[Impossibility of the treatment of inoperable liver multicystic echinococcosis due to adverse reactions to antihelminitics]</comment>
              <source>Vojnosanit Pregl</source>
              <year>2009</year>
              <volume>66</volume>
              <fpage>833</fpage>
              <lpage>9</lpage>
              <comment>Serbian.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(27 year old with echinococcal cysts developed ALT elevations after 2 months of albendazole therapy [800 mg daily] and also did not tolerate praziquantel [rash] leaving no options).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">19938764</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.amoruso.2009.176">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Amoruso</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Fuoti</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Miceli</surname>
                  <given-names>V</given-names>
                </name>
                <name name-style="western">
                  <surname>Zito</surname>
                  <given-names>E</given-names>
                </name>
                <name name-style="western">
                  <surname>Celano</surname>
                  <given-names>MR</given-names>
                </name>
                <name name-style="western">
                  <surname>De Giorgi</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Nebbia</surname>
                  <given-names>G</given-names>
                </name>
              </person-group>
              <comment>[Acute hepatitis as a side effect of albendazole: a pediatric case]</comment>
              <source>Pediatr Med Chir</source>
              <year>2009</year>
              <volume>31</volume>
              <fpage>176</fpage>
              <lpage>8</lpage>
              <comment>Italian.</comment>
              <annotation>
                <p>
                  <italic toggle="yes">(7 year old girl with pinworms developed jaundice during third course of albendazole [bilirubin 6.4 mg/dL, ALT 2200 U/L, GGT 58 U/L, Alk P 899 U/L], resolving rapidly upon stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">19839402</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF21">
            <element-citation publication-type="journal">
              <article-title>Drugs for parasitic infections.</article-title>
              <source>Treat Guidel Med Lett</source>
              <year>2013</year>
              <volume>11</volume>
              <supplement>Suppl</supplement>
              <fpage>e1</fpage>
              <lpage>31</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Brief description of drugs for parasitic infections in adults and children as well as a table of their major side effects: albendazole is the drug of choice for ascariasis, cutaneous larva migrans, pinworm, hookworm, whipworm, trichinellosis, and several less common parasitic infections; side effects include ALT elevations).</italic>
                </p>
              </annotation>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.namwanje.2011.181">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Namwanje</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Kabatereine</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Olsen</surname>
                  <given-names>A.</given-names>
                </name>
              </person-group>
              <article-title>A randomised controlled clinical trial on the safety of co-administration of albendazole, ivermectin and praziquantel in infected schoolchildren in Uganda.</article-title>
              <source>Trans R Soc Trop Med Hyg</source>
              <year>2011</year>
              <volume>105</volume>
              <fpage>181</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Trial comparing a 7 day course of the combination of albendazole, ivermectin and praziquantel to standard therapy in 235 children with lymphatic filariasis, schistosomiasis or helminthiasis found no differences in efficacy in decreasing egg counts or microfilariae and no change in liver tests).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">21353271</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.marin_zuluaga.2013.201">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Marin Zuluaga</surname>
                  <given-names>JI</given-names>
                </name>
                <name name-style="western">
                  <surname>Marin Castro</surname>
                  <given-names>AE</given-names>
                </name>
                <name name-style="western">
                  <surname>Perez Cadavid</surname>
                  <given-names>JC</given-names>
                </name>
                <name name-style="western">
                  <surname>Restrepo Gutierrez</surname>
                  <given-names>JC</given-names>
                </name>
              </person-group>
              <article-title>Albendazole-induced granulomatous hepatitis: a case report.</article-title>
              <source>J Med Case Rep</source>
              <year>2013</year>
              <volume>7</volume>
              <fpage>201</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(25 year old woman developed jaundice 2 weeks after starting albendazole [bilirubin 13.8 mg/dL, ALT 1649 U/L, Alk P 145 U/L], biopsy showing epithelioid granulomas, resolving within 2 months).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23889970</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.g_z_k___k.2013.82">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>G&#x000f6;z&#x000fc;k&#x000fc;&#x000e7;&#x000fc;k</surname>
                  <given-names>R.</given-names>
                </name>
              </person-group>
              <article-title>Albendazole-induced toxic hepatitis: A case report.</article-title>
              <source>Turk J Gastroenterol</source>
              <year>2013</year>
              <volume>24</volume>
              <fpage>82</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(28 year old man developed abnormal liver tests 20 days after starting albendazole for hydatid cyst disease [bilirubin not given, ALT 968 U/L, Alk P 209 U/L], resolving rapidly upon stopping and recurring within 3 days of restarting albendazole).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23794356</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.akhan.2014.1568">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Akhan</surname>
                  <given-names>O</given-names>
                </name>
                <name name-style="western">
                  <surname>Yildiz</surname>
                  <given-names>AE</given-names>
                </name>
                <name name-style="western">
                  <surname>Akinci</surname>
                  <given-names>D</given-names>
                </name>
                <name name-style="western">
                  <surname>Yildiz</surname>
                  <given-names>BD</given-names>
                </name>
                <name name-style="western">
                  <surname>Ciftci</surname>
                  <given-names>T</given-names>
                </name>
              </person-group>
              <article-title>Is the adjuvant albendazole treatment really needed with PAIR in the management of liver hydatid cysts? A prospective, randomized trial with short-term follow-up results.</article-title>
              <source>Cardiovasc Intervent Radiol</source>
              <year>2014</year>
              <volume>37</volume>
              <issue>6</issue>
              <fpage>1568</fpage>
              <lpage>74</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 39 patients with hydatid cysts treated with "puncture, aspiration, injection and reaspiration" [PAIR] with or without albendazole, initial success rates were 100%, but recurrence occurred only in those who did not receive albendazole; side effects occurred in 24% of albendazole treated subjects but their nature was not disclosed).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24464258</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.s_vg_n.2013.204">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>S&#x00131;vg&#x00131;n</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Eser</surname>
                  <given-names>B</given-names>
                </name>
                <name name-style="western">
                  <surname>Kaynar</surname>
                  <given-names>L</given-names>
                </name>
                <name name-style="western">
                  <surname>Kurnaz</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x00131;vg&#x00131;n</surname>
                  <given-names>H</given-names>
                </name>
                <name name-style="western">
                  <surname>Yazar</surname>
                  <given-names>S</given-names>
                </name>
                <name name-style="western">
                  <surname>Cetin</surname>
                  <given-names>M</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Encephalitozoon intestinalis: a rare cause of diarrhea in an allogeneic hematopoietic stem cell transplantation (HSCT) recipient complicated by albendazole-related hepatotoxicity.</article-title>
              <source>Turk J Haematol</source>
              <year>2013</year>
              <volume>30</volume>
              <fpage>204</fpage>
              <lpage>8</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(50 year old man with acute leukemia and hematopoietic cell transplant developed liver test abnormalities 5 days after starting albendazole for E. intestinalis [peak bilirubin 0.9 mg/dL, ALT 519 U/L, Alk P 255 U/L], resolving within 2 weeks of stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24385787</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.shah.2013.38">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Shah</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Mahapatra</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Shukla</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Bhatia</surname>
                  <given-names>S</given-names>
                </name>
              </person-group>
              <article-title>Recurrent acute hepatitis caused by albendazole.</article-title>
              <source>Trop Gastroenterol</source>
              <year>2013</year>
              <volume>34</volume>
              <fpage>38</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(7 year old boy had 4 episodes of jaundice, each arising shortly after a single dose of albendazole [bilirubin 2.3-5.5 mg/dL, ALT 1208-3005 U/L, Alk P 312-314 U/L], resolving within 10 days on each occasion).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">23923374</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.nandi.2013.1064">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Nandi</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Sarkar</surname>
                  <given-names>S.</given-names>
                </name>
              </person-group>
              <article-title>Albendazole-induced recurrent hepatitis.</article-title>
              <source>Indian Pediatr</source>
              <year>2013</year>
              <volume>50</volume>
              <fpage>1064</fpage>
              <annotation>
                <p>
                  <italic toggle="yes">(5 year old boy had 4 episodes of jaundice after receiving 2 to 3 days of albendazole [4th episode: bilirubin 11.5 mg/dL, ALT 2720 U/L, Alk P 1247 U/L, INR 1.6], resolving within 2 months of stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24382909</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.ben_fredj.2014.149">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Ben Fredj</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Chaabane</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Chadly</surname>
                  <given-names>Z</given-names>
                </name>
                <name name-style="western">
                  <surname>Ben Fadhel</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Boughattas</surname>
                  <given-names>NA</given-names>
                </name>
                <name name-style="western">
                  <surname>Aouam</surname>
                  <given-names>K</given-names>
                </name>
              </person-group>
              <article-title>Albendazole-induced associated acute hepatitis and bicytopenia.</article-title>
              <source>Scand J Infect Dis</source>
              <year>2014</year>
              <volume>46</volume>
              <fpage>149</fpage>
              <lpage>51</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(26 year old man with hydatic cyst developed jaundice 1 month after starting a second course of albendazole [bilirubin 20 mg/dL, ALT 2454 U/L, Alk P 198 U/L] with bone marrow suppression, resolving within 2 weeks of stopping).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24423162</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.hern_ndez.2014.231">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Hern&#x000e1;ndez</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bessone</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>S&#x000e1;nchez</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>di Pace</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Brahm</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Zapata</surname>
                  <given-names>R, A</given-names>
                </name>
                <name name-style="western">
                  <surname>Chirino</surname>
                  <given-names>R</given-names>
                </name>
                <etal/>
              </person-group>
              <article-title>Profile of idiosyncratic drug induced liver injury in Latin America: an analysis of published reports.</article-title>
              <source>Ann Hepatol</source>
              <year>2014</year>
              <volume>13</volume>
              <fpage>231</fpage>
              <lpage>9</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 176 reports of drug induced liver injury from Latin American published between 1996 and 2012, one case [non-fatal] was attributed to mebendazole, but none to albendazole).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">24552865</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.chalasani.2015.1340">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Chalasani</surname>
                  <given-names>N</given-names>
                </name>
                <name name-style="western">
                  <surname>Bonkovsky</surname>
                  <given-names>HL</given-names>
                </name>
                <name name-style="western">
                  <surname>Fontana</surname>
                  <given-names>R</given-names>
                </name>
                <name name-style="western">
                  <surname>Lee</surname>
                  <given-names>W</given-names>
                </name>
                <name name-style="western">
                  <surname>Stolz</surname>
                  <given-names>A</given-names>
                </name>
                <name name-style="western">
                  <surname>Talwalkar</surname>
                  <given-names>J</given-names>
                </name>
                <name name-style="western">
                  <surname>Reddy</surname>
                  <given-names>KR</given-names>
                </name>
                <etal/>
                <collab>United States Drug Induced Liver Injury Network</collab>
              </person-group>
              <article-title>Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study.</article-title>
              <source>Gastroenterology</source>
              <year>2015</year>
              <volume>148</volume>
              <fpage>1340</fpage>
              <lpage>52.e7</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, none were attributed to albendazole or any other anthelmintic agent).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25754159</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.amadodiago.2015.380">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Amado-Diago</surname>
                  <given-names>CA</given-names>
                </name>
                <name name-style="western">
                  <surname>Guti&#x000e9;rrez-Cuadra</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Armi&#x000f1;anzas</surname>
                  <given-names>C</given-names>
                </name>
                <name name-style="western">
                  <surname>Arna&#x000ed;z de Las Revillas</surname>
                  <given-names>F</given-names>
                </name>
                <name name-style="western">
                  <surname>G&#x000f3;mez-Fleitas</surname>
                  <given-names>M</given-names>
                </name>
                <name name-style="western">
                  <surname>Fari&#x000f1;as</surname>
                  <given-names>MC</given-names>
                </name>
              </person-group>
              <article-title>Echinococcosis: A 15-year epidemiological, clinical and outcome overview.</article-title>
              <source>Rev Clin Esp</source>
              <year>2015</year>
              <volume>215</volume>
              <fpage>380</fpage>
              <lpage>4</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Among 76 cases of hydatidosis seen at a Spanish referral hospital over a 15 year period, 94% had liver involvement, 58% men, ages 19 to 91 years, 37% received albendazole [usually with surgery or drainage], no mention of hepatotoxicity).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">26119089</pub-id>
            </element-citation>
          </ref>
          <ref id="Albendazole.REF.gomez.2015.124">
            <element-citation publication-type="journal">
              <person-group>
                <name name-style="western">
                  <surname>Gomez</surname>
                  <given-names>I</given-names>
                </name>
              </person-group>
              <comment>Gavara C, L&#x000f3;pez-And&#x000fa;jar R, Belda Ib&#x000e1;&#x000f1;ez T, Ramia &#x000c1;ngel JM, Moya Herraiz &#x000c1;, Orbis Castellanos F, Pareja Ibars E, et al</comment>
              <article-title>Review of the treatment of liver hydatid cysts.</article-title>
              <source>World J Gastroenterol</source>
              <year>2015</year>
              <volume>21</volume>
              <fpage>124</fpage>
              <lpage>31</lpage>
              <annotation>
                <p>
                  <italic toggle="yes">(Systematic review of the literature on therapy of hydatid cysts concludes that radical surgery with pre- and postoperative albendazole is the "best treatment option"; no discussion of adverse side effects).</italic>
                </p>
              </annotation>
              <pub-id pub-id-type="pmid">25574085</pub-id>
            </element-citation>
          </ref>
        </ref-list>
      </sec>
      <sec sec-type="link-group" id="Albendazole.OTHER_REFERENCE_LINKS">
        <title>OTHER REFERENCE LINKS</title>
        <list list-type="order">
          <list-item>
            <label>1</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&#x00026;db=pubmed&#x00026;pubmedfilters=true&#x00026;term=(Albendazole/AE)+AND+Human%5BMH%5D+AND+(drug+induced+liver+injury+OR+jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)">Recent References on Albendazole: from PubMed.gov</ext-link>
            </p>
          </list-item>
          <list-item>
            <label>2</label>
            <p>
              <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/results?term=Albendazole">Trials on Albendazole: from ClinicalTrials.gov</ext-link>
            </p>
          </list-item>
        </list>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
